Pfizer to obtain exclusive worldwide rights to develop and commercialize antibodies from Genovac academic collaboration

Fargo, North Dakota, USA, September 19, 2023 – Genovac, a leading contract research organization (CRO) that specializes in delivering advanced antibody discovery and biologic production solutions, announced today that it has entered into an exclusive licensing agreement with Pfizer, Inc. for selected antibodies generated by Genovac in collaboration with Yale University.

“We’re very excited to partner with Pfizer who will be responsible for future development and commercialization,” said Brian Walters, Genovac CEO.  “And we’re extremely grateful for our academic partner who helped identify the lead candidates, and we believe this successful collaboration can serve as a partnership model for future arrangements with research universities that have similar commercialization objectives.”

Under the terms of the license agreement, Genovac will receive an upfront payment and is eligible to receive future development and commercial milestone payments, plus royalties on future net sales of commercial products.